
Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells.

Journal: Cell Stem Cell

Publication Year: 2015

Authors: Tongbiao Zhao, Zhen-ning Zhang, Peter D Westenskow, Dilyana Todorova, Zheng Hu, Tongxiang Lin, Zhili Rong, Jinchul Kim, Jingjin He, Meiyan Wang, Dennis O Clegg, Yong-guang Yang, Kun Zhang, Martin Friedlander, Yang Xu

PubMed link: 26299572

Funding Grants: Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells, Synthetic Matrices for Stem Cell Growth and Differentiation , Developing induced pluripotent stem cells into human therapeutics and disease models, Induction of immune tolerance to human embryonic stem cell-derived allografts, Stem cell based treatment strategy for Age-related Macular Degeneration (AMD), Training Program in Stem Cell Biology and Engineering, The UCSB Laboratory for Stem Cell Biology and Engineering , UCSB Stem Cell Biology Training Program, Stem cell based treatment strategy for Age-related Macular Degeneration (AMD), Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration

Public Summary:

The breakthrough of induced pluripotent stem cell (iPSC) technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC (hiPSC)-derived cells is not well understood. Using a humanized mouse model (denoted Hu-mice) reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs exhibit local infiltration of antigen-specific T cells and associated tissue necrosis, indicating immune rejection of certain hiPSC-derived cells. In this context, autologous hiPSC-derived smooth muscle cells (SMCs) appear to be highly immunogenic, while autologous hiPSC-derived retinal pigment epithelial (RPE) cells are immune tolerated even in non-ocular locations. This differential immunogenicity is due in part to abnormal expression of immunogenic antigens in hiPSC-derived SMCs, but not in hiPSC-derived RPEs. These findings support the feasibility of developing hiPSC-derived RPEs for treating macular degeneration.

Scientific Abstract:

The breakthrough of induced pluripotent stem cell (iPSC) technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC (hiPSC)-derived cells is not well understood. Using a humanized mouse model (denoted Hu-mice) reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs exhibit local infiltration of antigen-specific T cells and associated tissue necrosis, indicating immune rejection of certain hiPSC-derived cells. In this context, autologous hiPSC-derived smooth muscle cells (SMCs) appear to be highly immunogenic, while autologous hiPSC-derived retinal pigment epithelial (RPE) cells are immune tolerated even in non-ocular locations. This differential immunogenicity is due in part to abnormal expression of immunogenic antigens in hiPSC-derived SMCs, but not in hiPSC-derived RPEs. These findings support the feasibility of developing hiPSC-derived RPEs for treating macular degeneration.

Source URL: <https://www.cirm.ca.gov/about-cirm/publications/humanized-mice-reveal-differential-immunogenicity-cells-derived-autologous>